Kornimate/medical-research-clean huggingface dataset:
development of exercise protocol for scoliosis using surface electromyography(s-emg)

Conditions: Idiopathic Scoliosis

Summary: there has been much effort in recent years to better understand the causes of idiopathic scoliosis (is). some studies suggested muscle imbalance as a cause of scoliosis based on asymmetric muscular activation. surface electromyography can evaluate asymmetrical muscular weakness. therefore, the peak amplitude values can be used to compare the side to side differences in paraspinal muscles. from these findings the investigators improve the exercise method of is according to muscle weakness and curve pattern.

design: prospective study setting: hospital rehabilitation department the investigators will check the muscular activation at bilateral paraspinal muscles with surface electromyography and curve type with simple radiography. intervention: after that the investigators educate asymmetrical stabilization exercise according to muscle weakness and curve pattern. main outcome measures: cobb angle

Eligibility criteria:
inclusion criteria: * x-ray shows a cobb angle of 10 degrees or higher. * patients 8 and older. exclusion criteria: * patients with spinal surgery * patients with scoliosis caused by cerebral palsy, muscle paralysis, polio, congenital spinal cord abnormalities, etc. * cobb angle less than 10 degrees and more than 40 degrees * patients with acute back pain

Keywords: surface emg, cobb angle, exercise, spinal curvatures
efficacy and safety of tiotropium in patients with copd and concomitant diagnosis of asthma

Conditions: Pulmonary Disease, Chronic Obstructive; Asthma

Summary: the primary objective of this study is to demonstrate the superiority of tiotropium compared to placebo in the treatment of patients with copd and a concomitant diagnosis of asthma


Eligibility criteria:
inclusion criteria: * diagnosis of copd and diagnosis of asthma before the age of 30 * current or ex-smokers with a cigarette smoking history of at least 10 pack-years * treatment with inhaled steroids at least 1 year before study entry * fev1 increase of more than 12% 30 min. after 400 mcg salbutamol or documented reversibility of 12% documented during the past 5 years * fev1 increase of more than 200 ml 30 min. after 400 mcg salbutamol or documented increase of 200 ml after reversibility test within the last 5 years * post bronchodilator fev1 less than 80% predicted normal (eccs) at visit 1 * post bronchodilator fev1 less than 70% of fvc at visit 1 exclusion criteria: * respiratory infection or exacerbation 6 weeks prior to visit 1 or during run-in period. * significant diseases other than copd or asthma * myocardial infarction within the last 6 months * unstable or life-threatening cardiac arrhythmia requiring intervention or change in therapy in the last year * hospitalisation for heart failure (nyha class iii or iv) within the last year * history of life-threatening pulmonary obstruction, cystic fibrosis or clinically evident bronchiectasis * known active tuberculosis * history of thoracotomy with pulmonary resection * history of cancer within the last 5 years (excluding treated basal cell carcinoma) * patients requiring oxygen therapy for more than 1 hour per day * patients currently in a pulmonary rehabilitation programme or who have completed such a programme within 4 weeks before visit 1 * known hypersensitivity to anticholinergic drugs or lactose
safety of paracetamol as antipyretic in treatment of dengue infection in adults

Conditions: Dengue; Transaminitis

Summary: the purpose of this study is to determine whether regular dosage of paracetamol causes transaminitis (hepatitis) and evaluate its potency in the treatment of dengue infection.


Eligibility criteria:
inclusion criteria: * patient age \>18 years * dengue infection diagnosed by ns1 antigen, dengue immunoglobulin m antibody, or polymerase chain reaction * admitted to the hospital * written informed consent from patient or attending relative able to and willing to give informed consent exclusion criteria: * other possible cause of fever other than dengue infection * pregnancy * unable to take medication * aminotransferase level above 3 times upper normal limit * allergy to paracetamol or tramadol * paracetamol indicated for condition other than dengue infection * critically ill patient who need icu or invasive ventilation support * history of cirrhosis * unable to comunicate

Keywords: paracetamol
a randomized, double blind, multi-center, active drug controlled, phase iii clinical trial to compare the safety and efficacy of dwp450 versus botox® in treatment of post stroke upper limb spasticity

Conditions: Spasticity; Stroke

Summary: purpose: this study is a randomized, double blind, multi-center, active drug controlled, phase iii clinical trial to compare the safety and efficacy of dwp450 versus botox® in treatment of post stroke upper limb(wrist, finger, elbow, thumb)spasticity.


Eligibility criteria:
inclusion criteria: 1. male or female adult patients 2. ≥ 6 weeks since the last stroke exclusion criteria: 1.patients with diagnosed neuromuscular disorders such as lamber-eaton syndrome, myasthenia gravis, or amyotrophic lateral sclerosis.
clinical study of the third dose immunization schedule of covid-19 inactivated vaccine, (vero cells) in adults aged 18 years and above (6 months after two doses)

Conditions: SARS-CoV-2 Infection

Summary: to evaluate the immunogenicity and safety of the third dose sars-cov-2 vaccine, inactivated (vero cell) in adults aged 18 years and above, who inoculated the third dose after 6 months since finished two doses schedule of coronavac or bbibp-corv.


Eligibility criteria:
inclusion criteria: 1. axillary temperature ≤37.0 ℃. 2. aged 18 years and above, after 6 months since finished two doses schedule of coronavac or bbibp-corv, or one does coronavac and one does bbibp-corv. 3. proven legal identity, could come each visit. 4. participants should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form. exclusion criteria: 1. persons with a clear history of sars-cov-2 infection. 2. using blood products after basic immunization or receiving immunosuppressive therapy. 3. participants who have a positive pregnancy test, or are breastfeeding, or plan to become pregnant, or plan to donate sperm or eggs from the screening to 6 months after vaccination. 4. allergic to the active substance in the vaccine, any inactive substance or substance used in the preparation process (aluminum hydroxide, glycine); 5. history of abnormal clinical manifestations and serious diseases to be excluded, including but not limited to nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism, bones and other system diseases, and a history of malignant tumors. 6. diseases beyond drug control, such as high blood pressure, diabetes, asthma. 7. those who developed acute disease within 2 weeks, or had symptoms of fever or upper respiratory tract infection within 7 days. 8. immunization with any vaccine within 14 days. 9. any other situations judged by investigators as not suitable for participating in this study.
ketamine infusion as a method of cerebral protection in children

Conditions: Brain Injuries

Summary: the study is devoted to the use of ketamine infusion in a subanesthetic dose in the postoperative period in children after surgical correction of congenital heart defects in children.

the study will examine the safety and effectiveness for neuroprotection of subanesthetic doses of ketamine in the postoperative period in children undergoing operations to correct septal congenital heart defects using cardiopulmonary bypass.

Eligibility criteria:
inclusion criteria: * age from 1 to 60 months * body weight from 3.5 to 20 kg * planned surgical intervention to correct a congenital heart defect (atrial or ventricular septal defect) with cpbё * the presence of informed consent for participation in the study signed by the child's legal representative exclusion criteria: * lack of informed consent of the patient and parents to participate in the study, * emergency and urgent surgical interventions; * the presence of clinically significant anemia; * hypo-thermic during operation, episodes of desaturation in the perioperative period; * the presence of another congenital heart diseases besides the atrial or ventricular septal defect, as well as their combination; * a history of central nervous system diseases; * an installed pacemaker; * hemodynamic instability requiring preoperative pharmacological and/or mechanical support; * any episodes of cerebrovascular accidents in the history or periop-erative period; * the presence of a patient with severe concomitant diseases that worsen mental and somatic conditio; * acute infection and exacerbation of chronic infection in the perioperative period; * concomitant autoimmune diseases; * the presence of malignant neoplasms; * surgical complications in the postoperative period.
life-tb ; long-term impacts on lung health and life after tuberculosis in korea

Conditions: Tuberculosis; Post Tuberculosis

Summary: this is a prospective, multicenter observational cohort study aimed at establishing a nationwide post-tb lung disease registry in korea. the study will enroll adult participants either undergoing treatment for pulmonary tuberculosis or with a history of treated tb. over a five-year follow-up period, the study will assess the long-term health consequences of tb, focusing on respiratory symptoms, radiological changes, pulmonary function, and quality of life.

"the life-tb (long-term impacts on lung health and life after tuberculosis in korea) study is a nationwide, prospective, multicenter observational cohort designed to systematically investigate the long-term impacts of tuberculosis (tb) on lung health and quality of life. this registry aims to fill the critical evidence gap in understanding post-tb lung disease (ptld) by enrolling adults with a current diagnosis of pulmonary tb or a history of tb treatment. participants will be recruited from six tertiary care centers across korea. eligible individuals include those aged 19 or older who are either undergoing anti-tb treatment or have completed it. exclusion criteria include extrapulmonary tb without lung involvement, age under 19, or refusal to consent. data will be collected at baseline and regularly over a five-year follow-up period. clinical variables include demographic information (age, sex, bmi, smoking status), tb-related history (sputum smear/culture, drug resistance, treatment outcomes), comorbidities, and current medications. clinical assessments involve standardized symptom scores (mmrc), chest imaging (x-ray and ct), spirometry, and validated instruments to assess quality of life (eq-5d-5l, promis, sgrq). laboratory data include blood tests (hba1c, lipids), hiv/hbv/hcv status, and urine and ecg assessments at baseline. participants will be followed annually, with interim assessments including imaging, spirometry, and symptom scoring at specified intervals. no study-specific interventions or additional imaging are required beyond routine care. chest cts will only be collected if obtained for clinical purposes. the study's primary objectives are to describe the prevalence and trajectory of ptld-related abnormalities and identify factors associated with poor outcomes. secondary analyses include trends in pulmonary function and quality of life over time, as well as health utilization patterns. statistical analyses include descriptive statistics and multivariable logistic regression to identify risk factors. all data will be anonymized and securely stored, following institutional and ethical guidelines. the study will contribute essential real-world data to inform national and international post-tb management strategies."

Eligibility criteria:
inclusion criteria: * age ≥19 years * diagnosed with pulmonary tb and either initiating or undergoing treatment or history of treated pulmonary tb exclusion criteria: * age \<19 years * extrapulmonary tb without lung involvement * refusal to provide informed consent

Keywords: post tuberculosis
effect of immunophenotype on prognosis of sepsis

Conditions: Sepsis; Septic Shock; Sepsis Syndrome

Summary: the popuse of this study is to assess the inflammatory immunophenotypes of sepsis patients are significantly correlated with prognosis, which may provide theoretical basis for precise immune regulation of sepsis.

the clinical characteristics and inflammatory/immune markers of sepsis patients were analyzed dynamically and followed up to one year after diagnosis. through latent category analysis, cluster analysis and other inflammatory immunophenotypes, the clinical characteristics of different inflammatory immunophenotypes and their relationship with the long-term prognosis of sepsis were clarified.

Eligibility criteria:
inclusion criteria:patients with sepsis 3 diagnostic criteria were admitted to icu; aged 18 or above; within 24 hours of diagnosis. - exclusion criteria:malignant tumor; autoimmune diseases; diseases of the blood system; hiv infection; history of high-dose glucocorticoid use (hydrocortisone 200mg/d or other hormone with equivalent titer, more than one week); pregnancy -

Keywords: immunophenotype
sevoflurane and percutaneous coronary intervention by stent

Conditions: Myocardial Infarction

Summary: increase in ck-mb after percutaneous coronary angioplasty more than 100% of baseline can represents a problem to the patients resulting in increase of morbidity and mortality. patients submitted of coronary angioplasty procedures can release in varying degrees of creatine kinase, mb isoform (ck - mb), on the order of 30% of all angioplasty. possibly patients who will receive sevoflurane experience a higher level of cardiac cell protection with lower incidence in the release of ck - mb values in excess of 100% baseline.

several published clinical studies have shown the benefit of using inhaled anesthetic agents in patients undergoing coronary artery bypass graft(cabg). these benefits involve functional state of the heart and reduction damage to the organ. these events are related to intracellular phenomena that result in intracellular calcium homeostasis giving physical and functional benefits to the heart. also disclosed is a modulation of the inflammatory response to endothelial level with resulting protective character to the coronary bed. patients submitted of coronary angioplasty procedures can release in varying degrees of creatine kinase, mb isoform (ck - mb), on the order of 30% of all angioplasty. even in smaller increases than 3 times baseline, a criterion that defines myocardial infarction, clinical impact can already be found. increase in ck-mb more than 100% of baseline can represents a problem to the patients. this elevation of ck - mb is associated with various factors such as age, characteristic of the lesion, clinical status of the patient, inferring that endovascular procedures of coronary, simple or complex, have associated myocardial damage, which depending on the intensity of the damage, results in increased morbidity and mortality. background and objectives: check for reduction in the percentage of patients that release ck -mb at levels above the 100% baseline in patients anesthetized with sevoflurane compared to the control group. possibly patients who will receive sevoflurane experience a higher level of cardiac cell protection with lower incidence in the release of ck - mb values in excess of 100% baseline.

Eligibility criteria:
inclusion criteria: 1. both gender. 2. patients with coronary artery disease candidates for coronary angioplasty stent. 3. cardiac catheterization on an urgent basis. 4. coronary angioplasty in elective and urgency. 5. age less than 80 years. exclusion criteria: 1. patients aged greater than or equal of 80 years. 2. angioplasty balloon catheter statement. 3. myocardial infarction with st-segment elevation. 4. angioplasty in saphenous vein grafts in patients after surgical revascularization. 5. patient pregnant. 6. dialytic insufficiency renal. 7. patients submited a urgent cardiac catheterization but not progress with coronary angioplasty stent.

Keywords: sevoflurane ck-mb
an observational study to evaluate efficacy and safety of risperidone long-acting injection for treatment of schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is to evaluate the long-term treatment efficacy, and safety of risperidone long-acting injection in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self).

this is an open-label (all people know the identity of the intervention), multi-center (conducted in more than one center), prospective (study following participants forward in time) and observational study of risperidone long-acting injection in participants with schizophrenia. the study consists of 2 parts: screening (that is, 28 days before study commences on day 1) and treatment (that is, week 1-24). all the eligible participants (after risperidone intolerance test during screening) will be receiving risperidone as intramuscular injection (injection of a substance into a muscle) at a dose of, either 25 milligram (mg), 37.5 mg or 50 mg every two weeks. efficacy of the participants will be primarily evaluated through positive and negative syndrome scale. participants' safety will be monitored throughout the study.

Eligibility criteria:
inclusion criteria: * male or female, age 18-65 years * participant must meet the diagnostic criteria for schizophrenia or schizophreniform disorder according to diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv)-tm * total course of disease no more than 5 years * according to physician's discretion, participants need to be changed to risperidone long-acting injection and other atypical anti-psychotic drug * participant or their legally acceptable representatives must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study exclusion criteria: * significant risk of suicidal or violent behavior, as clinically assessed by the investigator * have aggressive behavior and excited , restless * history or current symptoms of tardive dyskinesia; neuroleptic malignant syndrome; evidence of dysfunction of liver and kidney and other severe physical diseases; and severe, life-threatening allergic reaction to any drug * known hypersensitivity to risperidone * female participant who is pregnant or breastfeeding or planning to become pregnant during the study period

Keywords: schizophrenia risperidone risperdal consta oral antipsychotic
efficacy and safety of gadobutrol 1.0 molar (gadovist) for breast magnetic resonance imaging (mri)

Conditions: Breast Cancer

Summary: the purpose of this study is to look at the efficacy (how does it work) and safety of gadobutrol when used for obtaining mr images of both breasts.women with a recent diagnosis of breast cancer by mammogram (x-ray examination of the breasts) may benefit from mri of the breasts as mri may detect additional breast cancers


Eligibility criteria:
inclusion criteria: * recent histologically proven diagnosis of breast cancer after having obtained x-ray mammography (xrm) of both breasts (according to american college of radiology \[acr\] and performed no longer than 6 weeks prior to enrollment into the study) and has been referred for a contrast-enhanced magnetic resonance mammography (mrm) prior to surgery of the breast. * if female, a digital xrm is required if any of the following criteria is met: * a. patient is younger than 50 years; * b. patient has heterogeneously or extremely dense breasts; * c. is not post-menopausal (post-menopause defined as at least 12 months prior to inclusion without menstruation). * if female of childbearing potential, mrm should be performed on the 7-14th day of the menstrual cycle. * has an estimated glomerular filtration rate (egfr) value \>/= 60 ml/min/1.73m\^2 derived from a serum creatinine result within 2 weeks prior to study enrollment. exclusion criteria: * is a female patient who is pregnant or lactating * has any contraindication to the mrm examination (e.g. metal implants, phobia) or the use of gadolinium-containing contrast agents. * has received any contrast agent within 24 hours prior to the study mrm, or is scheduled to receive any contrast agent within 24 hours after the study mrm. * has severe cardiovascular disease (e.g., known long qt syndrome, acute myocardial infarction \[\< 14 days\], unstable angina, congestive heart failure new york heart association class iv) or acute stroke (\< 48 hours)). * has acute renal insufficiency of any severity due to hepato-renal syndrome or in the peri-operative liver transplantation period or who has acute or chronic moderate or severe renal insufficiency (glomerular filtration rate \< 60 ml/min/1.73m\^2). * has received chemotherapy or hormonal therapy for breast cancer within 6 months. * has received hormone replacement therapy within 4 weeks prior to study drug administration. * is scheduled or likely to require a surgery and/or biopsy in the time period up to 24 hours following study drug application * has prior excisional biopsy or breast surgery less than 6 months before enrollment and between xrm and study mrm

Keywords: breast cancer gadobutrol-enhanced mri mammography diagnostic imaging
patients with chronic knee pain treated with conventional radiofrequency of the genicular nerves

Conditions: Chronic Knee Pain

Summary: management of chronic knee pain remains a challenge to the treating physician. a radiofrequency treatment of the genicular nerves is a not yet established but promising technique. this procedure is minimal invasive and has few adverse events. for these reasons it can be advantageous and fulfilling the unmet needs of these chronic knee pain patients warranting further research of its efficacy. to investigate this efficacy, all patients treated with radiofrequency ablation in the multidisciplinary chronic pain center between 1 september 2017 and 31 december 2019 with exclusion of patients with chronic widespread pain, will be retrospectively analyzed in a single-center cohort.

this project has as primary objective the evaluation of treatment success of a conventional radiofrequency treatment of the genicular nerves in patients diagnosed with chronic knee pain due to osteoarthritis of the knee or persistent post-surgical pain (ppsp) at six weeks post treatment. secondary objectives are evaluation of treatment effect at a third time point at the end of the inclusion period, subgroup analysis of treatment success based on indication to treatment, evaluation of subjective functional improvement and change in analgesics, estimation of the duration of effect of the treatment and adverse events. this study includes all patients treated with radiofrequency ablation in the multidisciplinary chronic pain center in ziekenhuis oost-limburg, campus sint-barbara between 1 september 2017 and 31 december 2019 with exclusion of patients with chronic widespread pain. the main study outcome is the proportion of patients with a global perceived effect of at least 50% at 6 weeks post intervention. secondary outcomes include reduction in pain intensity, measured by numeric rating scale (nrs) at six weeks and at a third time point, global perceived effect at a third time point, subjective change in physical functioning, duration effect of the treatment, use of strong opioids, and adverse events.

Eligibility criteria:
inclusion criteria: * all patients with chronic knee pain who qualify for a conventional rf treatment of the genicular nerves exclusion criteria: * a negative diagnostic block with lidocaine 2% 1 ml of the three genicular nerves defined as less than 50% pain reduction * chronic widespread pain

Keywords: conventional radiofrequency